YARAL Pharma Secures Exclusive Rights To Generic Levothyroxine Capsules In U.S.

YARAL Pharma Inc., the U.S. generics arm of IBSA (Institut Biochimique SA), a multinational pharmaceutical headquartered in Lugano, Switzerland, has announced its exclusive role as the supplier for authorized generic levothyroxine sodium capsules in the United States. These capsules are vital in treating hypothyroidism.

Stephen Beckman, CEO of Yaral Pharma said, “When it comes to managing hypothyroidism, not all levothyroxine medications are created equal. Each year, millions of patients are treated with levothyroxine. For those who have trouble tolerating traditional levothyroxine tablets, the answer may lie in the dosage form. YARAL is pleased to offer patients a high-quality gel capsule product, specially formulated to improve the tolerability of LT4 therapy, supported by continuity of supply, and an exceptional level of customer service.”

YARAL Pharma offers Levothyroxine Sodium Capsules, a specialized gel-cap formulation crafted to enhance absorption and tolerability compared to traditional levothyroxine tablets. Available in twelve different strengths, these capsules are composed of just four essential ingredients: levothyroxine, gelatin, glycerin, and water. Importantly, they are free from sugars, dyes, alcohol, wheat starch (gluten), and lactose. This makes them particularly beneficial for patients with hypothyroidism who may have allergies or sensitivities to typical tablet ingredients, or who suffer from specific gastrointestinal conditions.